Bausch & Lomb Buys Eyeonics, Enters Premium IOL Market With Crystalens
This article was originally published in The Gray Sheet
Executive Summary
Bausch & Lomb will enter the fast-growing premium intraocular lens market for the first time through its acquisition of Crystalens maker Eyeonics under a pact announced Jan. 20
You may also be interested in...
NicOx finds new partner Bausch & Lomb for Phase II Glaucoma Candidate
Deal shows - once again - that all is not lost when Big Pharma hands back a product
Abbott Gains Synchrony Accommodating IOL Via $400 Mil. Visiogen Purchase
Abbott will strengthen its premium intraocular lens offerings and enter the accommodating IOL market for the first time through its $400 million purchase of Visiogen, announced Sept. 2
Abbott Gains Synchrony Accommodating IOL Via $400 Mil. Visiogen Purchase
Abbott will strengthen its premium intraocular lens offerings and enter the accommodating IOL market for the first time through its $400 million purchase of Visiogen, announced Sept. 2